Targeting HDAC6 Restores Docetaxel Chemotherapy Sensitivity in Resistant Prostate Cancer Cells
Researchers have demonstrated that selectively inhibiting histone deacetylase 6 overcomes acquired docetaxel resistance in cellular models of castration-resistant prostate cancer.

